Alpha 2.0
Login Register
» Authors » Dimitrios Arkilo

Dimitrios Arkilo

Explore the profile of Dimitrios Arkilo including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 19
Citations 107
Followers 0
Related Specialties
Neurology
Pediatrics
Pharmacology
Top 10 Co-Authors
Mahnaz Asgharnejad
Ronald Thibert
Shafali Jeste
Polyna Khudyakov
Sonya Wang
Antonio Laurenza
Samuel Hsiao
Wei Yin
Nitin Agarwal
Lawrence T Reiter
Published In
J Child Neurol
Epilepsy Res
Br J Clin Pharmacol
Eur J Paediatr Neurol
Epilepsy Behav
Affiliations
Soon will be listed here.
Recent Articles
1.
A Randomized Phase 2 KINETIC Trial Evaluating SAGE-324/BIIB124 in Individuals with Essential Tremor
Elble R, Ondo W, Lyons K, Qin M, Garafola S, Hersh B, et al.
Mov Disord . 2024 Feb; 39(4):733-738. PMID: 38357797
Background: SAGE-324/BIIB124 is an investigational positive allosteric modulator of GABA receptors. Objective: KINETIC (NCT04305275), a double-blind, randomized, placebo-controlled, phase 2 study, evaluated SAGE-324/BIIB124 in individuals with essential tremor (ET). Methods:...
2.
Efficacy, safety, and tolerability of soticlestat as adjunctive therapy for the treatment of seizures in patients with Dup15q syndrome or CDKL5 deficiency disorder in an open-label signal-finding phase II study (ARCADE)
Demarest S, Jeste S, Agarwal N, Arkilo D, Asgharnejad M, Hsiao S, et al.
Epilepsy Behav . 2023 Apr; 142:109173. PMID: 37011526
Objective: Chromosome 15q duplication (Dup15q) syndrome and cyclin‑dependent kinase-like 5 deficiency disorder (CDD) are rare neurodevelopmental disorders associated with epileptic encephalopathies, with a lack of specifically approved treatment options. ARCADE...
3.
Randomized controlled study to evaluate the efficacy and safety of soticlestat as adjunctive therapy in adults with complex regional pain syndrome
Ratcliffe S, Arkilo D, Asgharnejad M, Bhattacharya S, Harden R
Pain Med . 2022 Dec; 24(7):872-880. PMID: 36538782
Objective: The objective was to investigate the efficacy and safety of soticlestat as adjunctive therapy in participants with complex regional pain syndrome (CRPS). Design: A proof-of-concept phase 2a study, comprising...
4.
A phase 2, randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of soticlestat as adjunctive therapy in pediatric patients with Dravet syndrome or Lennox-Gastaut syndrome (ELEKTRA)
Hahn C, Jiang Y, Villanueva V, Zolnowska M, Arkilo D, Hsiao S, et al.
Epilepsia . 2022 Jul; 63(10):2671-2683. PMID: 35841234
Objective: Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) are rare treatment-resistant childhood epilepsies classed as developmental and epileptic encephalopathies. ELEKTRA investigated the efficacy and safety of soticlestat (TAK-935) as adjunctive...
5.
A phase 1 study to evaluate the safety, tolerability and pharmacokinetics of TAK-041 in healthy participants and patients with stable schizophrenia
Yin W, Han D, Khudyakov P, Behrje R, Posener J, Laurenza A, et al.
Br J Clin Pharmacol . 2022 Mar; 88(8):3872-3882. PMID: 35277995
Aims: TAK-041 (NBI-1065846), an orally available, investigational, small molecule agonist of GPR139, an orphan G-protein-coupled receptor, has shown promise in preclinical studies for the treatment of symptoms associated with schizophrenia....
6.
Safety, pharmacokinetics and pharmacodynamics of TAK-418, a novel inhibitor of the epigenetic modulator lysine-specific demethylase 1A
Yin W, Arkilo D, Khudyakov P, Hazel J, Gupta S, Quinton M, et al.
Br J Clin Pharmacol . 2021 May; 87(12):4756-4768. PMID: 33990969
Aims: Dysregulation of histone methylation epigenetic marks may result in intellectual and developmental disability, as seen in Kabuki syndrome. Animal data suggest that increasing histone methylation by inhibiting lysine-specific demethylase...
7.
A phase 1b/2a study of soticlestat as adjunctive therapy in participants with developmental and/or epileptic encephalopathies
Halford J, Sperling M, Arkilo D, Asgharnejad M, Zinger C, Xu R, et al.
Epilepsy Res . 2021 May; 174:106646. PMID: 33940389
Objective: To evaluate the safety, tolerability, and pharmacokinetics of soticlestat, a first-in-class cholesterol 24-hydroxylase inhibitor, in adults with developmental and/or epileptic encephalopathies (DEE). Methods: The study comprised a 30-day, randomized,...
8.
In Vitro Metabolism of Slowly Cleared G Protein-Coupled Receptor 139 Agonist TAK-041 Using Rat, Dog, Monkey, and Human Hepatocyte Models (HepatoPac): Correlation with In Vivo Metabolism
Kamel A, Bowlin S, Hosea N, Arkilo D, Laurenza A
Drug Metab Dispos . 2020 Dec; 49(2):121-132. PMID: 33273044
Hepatic metabolism of low-clearance compound TAK-041 was studied in two different in vitro model systems using rat, dog, monkey, and human suspended cryopreserved hepatocytes and HepatoPac micropatterned coculture model primary...
9.
Emergency Department Use of Neuroimaging in Children and Adolescents Presenting with Headache
Cain M, Arkilo D, Linabery A, Kharbanda A
J Pediatr . 2018 Jun; 201:196-201. PMID: 29908647
Objectives: To evaluate emergency department use and outcomes of neuroimaging for headache in a free-standing children's hospital system. Study Design: We prospectively enrolled children aged 6-18 years who presented to...
10.
Multisite Semiautomated Clinical Data Repository for Duplication 15q Syndrome: Study Protocol and Early Uses
Ajayi O, Smith E, Viangteeravat T, Huang E, Nagisetty N, Urraca N, et al.
JMIR Res Protoc . 2017 Oct; 6(10):e194. PMID: 29046268
Background: Chromosome 15q11.2-q13.1 duplication syndrome (Dup15q syndrome) is a rare disorder caused by duplications of chromosome 15q11.2-q13.1, resulting in a wide range of developmental disabilities in affected individuals. The Dup15q...